Eun Ran Kim, Jeong Su Park, Jin Hee Kim, Ji Young Oh, In Jeong Oh, Da Hyun Choi, Yu seol Lee, I. Seul Park, SeungWon Kim, Da Hyun Lee, Jae Hee Cheon, Jin‐Woo Bae, Minyoung Lee, Jin Won Cho, In Bok An, Eun Joo Nam, Sang‐In Yang, Myung‐Shik Lee, Soo Han Bae, Yong‐ho Lee – 11 November 2021

Juan Yang, Jianming Ye, Tengfei Ma, Fangfang Tang, Li Huang, Zhen Liu, Song Tian, Xu Cheng, Li Zhang, Zhenli Guo, Fuping Tu, Miao He, Xueming Xu, Xiaojuan Lu, Yanyang Wu, Xiaoli Zeng, Jiahua Zou, Xiangcai Wang, Weijie Peng, Peng Zhang – 11 November 2021

Yana Davidov, Keren Tsaraf, Oranit Cohen‐Ezra, Mariya Likhter, Gil Ben Yakov, Itzchak Levy, Einav G. Levin, Yaniv Lustig, Orna Mor, Galia Rahav, Ziv Ben Ari – 11 November 2021 – The BNT162b2 messenger RNA (mRNA) vaccine against severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) has been shown to be safe and effective in immunocompetent patients. The safety and efficacy of this vaccine in liver transplantation (LT) recipients is still under evaluation. The objective of this study was to assess the safety and efficacy of the BNT162b2 vaccine among transplant recipients.

Julieta Politi, Juan‐Miguel Guerras, Marta Donat, María J. Belza, Elena Ronda, Gregorio Barrio, Enrique Regidor – 11 November 2021

To introduce artificial intelligence in the management of liver disease for clinicians. This program spans several applications of AI in hepatology spanning administrative datasets, radiology, pathology and multi-omics. This interactive session will spur further dialogue and research into this field and provide a platform to build on for future CRW events.

The 2021 AASLD/ASGE Endoscopy Course at AASLD will foster discussions on the management of challenging clinical scenarios encountered by hepatologists and gastroenterologists that require endoscopic consideration. This evidence-based course includes expert opinions on potential knowledge gaps or clinical controversies. The session has a case-based, interactive format that emphasizes good clinical practice, emerging paradigms, innovation, and safety concerns.

What pressing challenges do patients with advanced liver disease and/or liver cancer face as they consider treatment options with their physicians? Complex diseases must be managed by a multidisciplinary team to achieve optimal outcomes. At this program, faculty will review effective strategies to incorporate multidisciplinary approaches in the management of liver cancer, portal hypertension, and substance-use disorders.

Hepatocellular carcinoma (HCC) management strategies have been revolutionized over the last five years. Combination therapies are now standard of care for advanced HCC patients, and novel emerging therapies are currently being tested and approved. At this exciting talk, experts will review the many opportunities to improve management, quality of life and outcomes of patients with advanced HCC.

Precision medicine in NAFLD may be within reach due to exciting advances in AI technology and genomics. At this year’s NAFLD SIG program, renowned experts share new insights on precision medicine for NAFLD, including recent trends and developments in NAFLD genomics and transcriptomics, and advances in artificial intelligence for NAFLD diagnosis.

Available, safe, and effective oral antiviral therapies help manage complications in patients with HBV, who are at increased risk for infection reactivation as they age due to increased exposure to biologics for various comorbidities. Experts will share advances in novel diagnostic and prognostic biomarkers, when hepatologists should consider prophylactic antiviral therapy, and research advances toward an HBV cure.